The following are today's upgrades for Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
The following are today's upgrades for Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.
The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
The following are today's upgrades for Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
The following are today's upgrades for Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
The following are today's upgrades for Validea's Growth/Value Investor model based on the published strategy of James P. O'Shaughnessy. This two strategy approach offers a large-cap value model and a growth approach that looks for persistent earnings growth and strong relative
The Robinhood financial services company took the stock-trading world by storm with its millennial-focused investing app, which offers low or no fees (depending on the service) and a user-friendly platform geared toward novice investors. The company also publishes a regularly up
In early trading on Tuesday, shares of JD.com, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.6%. Year to date, JD.com, registers a 100.8% gain.
In early trading on Tuesday, shares of Oracle topped the list of the day's best performing components of the S&P 500 index, trading up 4.5%. Year to date, Oracle registers a 6.5% gain.
In early trading on Tuesday, shares of Exxon Mobil topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.9%. Year to date, Exxon Mobil has lost about 38.3% of its value.
The Food and Drug Administration has given the nod to a novel new COVID-19 test. The regulator announced Monday that it granted an emergency use authorization (EUA) for SalivaDirect, a diagnostic solution developed by the Yale School of Public Health.
(RTTNews) - Shares of Greenpro Capital Corp. (GRNQ) are currently soaring over 85% on Tuesday morning after the company announced that it will spin off D'Swiss shares to its shareholders.
The NASDAQ showed the S&P how it’s done on Monday by soaring 1% and closing at a record high. Meanwhile, its counterpart continues to dilly-dally just under its own milestone.
In the end though, they both started the week with solid gains amid another slow summer sessio
You may not have realized it, but this past Friday, Aug. 14, was one of the most important days of the third quarter. That's because it marked the filing deadline for Form 13F with the Securities and Exchange Commission.
The top six pay-TV operators lost a combined 1.6 million subscribers last quarter, and that number would've been worse without the FCC's Keep Americans Connected pledge. AT&T (NYSE: T) CEO John Stankey said he expects cord-cutting to get worse in the second half of the year
The National Bank of Hungary (NBH) is likely to leave interest rates unchanged next week based on a Reuters poll of economists, some of whom expect another cut in its base rate this year after a deeper-than-expected slump in second-quarter economic output.
After posting eye-popping growth of 3,560% so far this year, it's safe to say that Novavax (NASDAQ: NVAX) has already made a handful of millionaires. On the other hand, it's unlikely that the business -- which describes itself as a "late-stage biotechnology company" -- can repli